Drug intelligence / Profile preview

ENDO-995

Development stage: Preclinical
Lead developer: EndoCyclic Therapeutics
Modality: Peptides

Overview

ENDO-995 is an investigational peptide therapeutic developed by EndoCyclic Therapeutics, designed to target and treat malignant solid tumors. It is part of an innovative platform that utilizes cell-permeating, pH-sensitive peptides engineered to selectively act within diseased tissue, aiming for precise therapeutic effects without the systemic toxicity associated with traditional treatments like hormones or radiation.

Beyond the preview

Go deeper on ENDO-995.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENDO-995.

Explore the full profile